Jones Financial Companies Lllp Has $35.72 Million Holdings in Abbott Laboratories (NYSE:ABT)

Jones Financial Companies Lllp lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 18.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 315,771 shares of the healthcare product maker’s stock after acquiring an additional 49,087 shares during the quarter. Jones Financial Companies Lllp’s holdings in Abbott Laboratories were worth $35,717,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Noble Wealth Management PBC bought a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $26,000. Peterson Financial Group Inc. bought a new position in Abbott Laboratories in the 3rd quarter valued at approximately $32,000. Wingate Wealth Advisors Inc. acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $34,000. Newbridge Financial Services Group Inc. acquired a new position in Abbott Laboratories during the 4th quarter worth about $37,000. Finally, JDM Financial Group LLC increased its position in shares of Abbott Laboratories by 51.3% during the third quarter. JDM Financial Group LLC now owns 363 shares of the healthcare product maker’s stock worth $41,000 after buying an additional 123 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Trading Up 1.6 %

Shares of Abbott Laboratories stock opened at $137.99 on Friday. The firm’s 50-day moving average price is $123.08 and its 200 day moving average price is $117.83. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $138.37. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $239.32 billion, a PE ratio of 18.04, a P/E/G ratio of 2.52 and a beta of 0.75.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, meeting the consensus estimate of $1.34. The firm had revenue of $10.97 billion for the quarter, compared to analysts’ expectations of $11.03 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company’s revenue was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.19 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.71%. The ex-dividend date of this dividend is Tuesday, April 15th. Abbott Laboratories’s dividend payout ratio is currently 30.85%.

Insider Buying and Selling

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total value of $3,054,573.50. Following the sale, the executive vice president now owns 125,697 shares of the company’s stock, valued at approximately $16,152,064.50. The trade was a 15.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ABT. Stifel Nicolaus increased their target price on shares of Abbott Laboratories from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Evercore ISI boosted their price objective on Abbott Laboratories to $136.00 and gave the company a “buy” rating in a research note on Thursday, January 2nd. Barclays reaffirmed an “overweight” rating and issued a $158.00 price target (up previously from $149.00) on shares of Abbott Laboratories in a report on Monday, January 27th. UBS Group raised their price target on Abbott Laboratories from $146.00 to $148.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $135.00 price objective on shares of Abbott Laboratories in a report on Tuesday, January 21st. Four analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $133.06.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.